



EXPRESS MAIL NO. EV335392610US
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Martin A. Cheever and David J. Peace
Application No. : 10/671,328
Filed : September 24, 2003
For : IMMUNE REACTIVITY TO EXPRESSED ACTIVATED
ONCOGENES FOR DIAGNOSIS AND TREATMENT OF
MALIGNANCY

Art Unit : 1764
Docket No. : 920010.525C3
Date : July 14, 2004

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 08/473,762, filed June 7, 1995, now abandoned; which is a divisional of Application No. 08/251,590, filed May 31, 1994, now U.S. Patent 5,601,989; which is a divisional of U.S. Application No. 07/820,409, filed January 13, 1992, now U.S. Patent 5,320,947; which is a continuation-in-part of U.S. Application 07/470,645, filed January 26, 1990, now abandoned. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.


As to any reference previously supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Richard G. Sharkey, Ph.D.
Registration No. 32,629

Customer No. 00500

RGS:ljt

Enclosures:

Form PTO-1449 (6 Sheets)

V496129

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.525C3APPLICATION NO.
10/671,328

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever et al.

FILING DATE

September 24, 2003

GROUP ART UNIT

1764

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,376,110	03/08/83	David et al.	436	513	
	AB	4,411,990	10/25/83	Salmon et al.	435	32	
	AC	4,643,968	02/17/87	Weaver	435	32	
	AD	4,820,631	04/11/89	Lacal et al.	435	6	
	AE	4,861,589	08/29/89	Ju et al.	424	93	
	AF	6,015,567	01/18/00	Hudziak et al.	424	277.1	
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	EP 330878 A2	09/06/89	EPO		
	AL					
	AM					
	AN					
	AO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Balmain et al., "An Approach to the Molecular Mechanism of Cancer Induction," Journal of Pathology 149: 3-8, 1986
	AQ	Balmain, A., "Transforming ras oncogenes and multistage carcinogenesis," British Journal of Cancer 51: 1-7, 1985.
	AR	Ben-Mahrez, K., et al., "Circulating Antibodies Against c-myc Oncogene Product in Sera of Colorectal Cancer Patients," <i>Int. J. Cancer</i> 46:35-38, 1990.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criterion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.525C3APPLICATION NO.
10/671,328**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever et al.

FILING DATE

September 24, 2003

GROUP ART UNIT

1764

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BC	Ben-Mahrez, K., et al., "Detection of circulating antibodies against c-myc protein in cancer patient sera," <i>Vr. J. Cancer</i> 57: 529-534, 1988.
	BD	Bloch, A., "Growth and differentiation signals as determinants of cancer cell proliferation," <i>Chemical Abstracts</i> 111(21): Abstract # 192290z, 1989.
	BE	Bodmer, W., "T-cell immune response to cancer--a new look," <i>Hum. Immunol.</i> 30(4): 259-261, 1991.
	BF	Bos et al., "Prevalence of ras gene mutations in human colorectal cancers," <i>Nature</i> 327: 293-297, 1987.
	BG	Bos, J., "ras Oncogenes in Human Cancer: A Review," <i>Cancer Research</i> 49: 4682-4689, 1989.
	BH	Bos, J., "The ras gene family and human carcinogenesis," <i>Mutation Research</i> 195: 255-271, 1988.
	BI	Brown et al., "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies," <i>Journal of Biological Chemistry</i> 255(11):4980-4983, 1980.
	BJ	Carbone and Bevan, "Induction of Ovalbumin-specific Cytotoxic T Cells By In Vivo Peptide Immunization," <i>Journal of Experimental Medicine</i> 169: 603-612, March 1989.
	BK	Carney et al., "Monoclonal Antibodies for Detecting Oncogenic ras Proteins in Cancer Cells," <i>Clinical Chemistry</i> 34: 1698-1699, 1988.
	BL	Carney, W., "Human tumor antigens and specific tumor therapy," <i>Immunology Today</i> 9(12):363-364, 1988.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criterion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.525C3		APPLICATION NO. 10/671,328	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Martin A. Cheever et al.			
				FILING DATE September 24, 2003		GROUP ART UNIT 1764	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	CB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CC	Cease, K., "NCI Clinical Investigator Award," NIH Grant No. CA001323-01, 1988. Internet, NIH CRISP Database. Accessible at http://crisp.cit.nih.gov .					
	CD	Chardin, P., "The ras superfamily proteins," Biochimie 70:865-868, 1988.					
	CE	"Clinical Laboratory Methods for Detection of Cellular Immune Function," (eds.), Stites, Stobo and Wells, Basic and Clinical Immunology (Sixth edition) Appleton & Lange, 1987, pp. 295-298.					
	CF	Cubie and Norval, "Humoral and Cellular Immunity to Papillomavirus in Patients With Cervical Dysplasia," <i>Journal of Medical Virology</i> 24: 85-95, 1988.					
	CG	Disis, M.L. et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2/neu, on Oncogenic Self-Protein," <i>The Journal of Immunology</i> 156: 3151-3158, 1996.					
	CH	Dotsika and Sanderson, "A fluorometric assay for determining cell growth in lymphocyte proliferation and lymphokine assays," Chemical Abstracts 108(5): abstract # 35974w, 1988.					
	CI	Drebin et al., "Preliminary Evidence of an Association Between an Activated Cellular Transforming Gene and a Tumor-Specific Transplantation Antigen," UCLA Symposium on Molec. & Cell Biology 24:223-225, 1982.					
	CJ	Feramisco et al., "Microinjection of the Oncogene Form of the Human H-ras (T-24) Protein Results in Rapid Proliferation of Quiescent Cells," <i>Cell</i> 38:109-117, 1984.					
	CK	Forrester et al., "Detection of high incidence of K-ras oncogenes during human colon tumorigenesis," <i>Nature</i> 327:298-303, 1987.					
	CL	Gehly et al., "Chimeric BCR-abl Messenger RNA as a Marker for Minimal Residual Disease in Patients Transplanted for Philadelphia Chromosomes-Positive Acute Lymphoblastic Leukemia," <i>Blood</i> 78:458-465, 1991.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criterion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.525C3APPLICATION NO.
10/671,328**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever et al.

FILING DATE

September 24, 2003

GROUP ART UNIT

1764

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DC	Hand et al., "Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas," <i>Proc. Natl. Acad. Sci. USA</i> 81:5227-5231, 1984.
DD	Huber, B., "Therapeutic opportunities involving cellular oncogenes: novel approaches fostered by biotechnology," <i>FASEB Journal</i> 3:5-13, 1989.
DE	Itoh, K. et al., "Autologous Tumor-Specific Cytotoxic T Lymphocytes in the Infiltrate of Human Metastatic Melanomas," <i>Journal of Experimental Medicine</i> 168: 1419-1441, October 1988.
DF	Jung and Schluesener, "Human T Lymphocytes Recognize a Peptide of Single Point-mutated, Oncogenic ras Proteins," <i>Journal of Experimental Medicine</i> 173:273-276, 1991. Marx, J., "Gene Signals Relapse of Breast, Ovarian Cancers," <i>Science</i> 244:654-655, 1989.
DG	Knuth, A. et al., "T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures," <i>Proc. Natl. Acad. Sci. USA</i> 81: 3511-3515, June 1984.
DH	Lurquin, C. et al., "Structure of the Gene of Tum Transplantation Antigen P91A: The Mutated Exon Encodes a Peptide Recognized with L ^d by Cytolytic T Cells," <i>Cell</i> 58: 292-303, July 28, 1989.
DI	Maher, V.E. et al., "Mutant Oncogene and Tumor Suppressor Gene Products and Fusion Proteins Created by Chromosomal Translocations as Targets for Cancer Vaccines," in <i>Peptide-Based Cancer Vaccines</i> , Medical Intelligence Unit 24, Kast, W.M (ed.), Eurekah.com/Landes Biosciences, Georgetown, Texas, 2000, pgs. 17-39.
DJ	McLaughlin et al., "Alternative Forms of the BCR-ABL Oncogene Have Quantitatively Different Potencies for Stimulation of Immature Lymphoid Cells," <i>Mol. and Cell. Biol.</i> 9:1866-1874, 1989.
DK	McLaughlin et al., "In Vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome," <i>Proc. Natl. Acad. Sci. USA</i> 84:6558-6562, 1987.
DL	Nathan and Oski (eds.), <i>Hematology Of Infancy and Childhood</i> 2, 4th ed., W. B. Saunders Co., Philadelphia, p. 1134.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criterion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 920010.525C3	APPLICATION NO. 10/671,328
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Martin A. Cheever et al.	
		FILING DATE September 24, 2003	GROUP ART UNIT 1764

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
EB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

EC	Nigro et al., "Mutations in the p53 gene occur in diverse human tumour types," Nature 342:705-707, 1989.
ED	Niman et al., "Anti-peptide antibodies detect oncogene-related proteins in urine," Proc. Natl. Acad. Sci. USA 82: 7924-7928, 1985.
EE	Osband and Ross, "Problems in the investigational study and clinical use of cancer immunotherapy," <i>Immunology Today</i> 11(6): 193-195, June 1990.
EF	Peace et al., "T Cells Immune To The p21 Product Of An Activated ras Proto-Oncogene Can Be Elicited By Immunization With Peptides Corresponding To The Mutated Protein Segment," FASEB Journal 4(7): Abstract # 1854, p. A2013, 1990.
EG	Raines and Ross, "Platelet-derived Growth Factor," Journal of Biological Chemistry 257(9):5154-5160, 1982.
EH	Reddy et al., "A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene," Nature 300: 149-152, 1982.
EI	Rodenhuis et al., "Mutational Activation of the K-ras Oncogene: A Possible Pathogenetic Factor in Adenocarcinoma of the Lung," New England Journal of Medicine 317(15):929-935, 1987.
EJ	Santos and Nebreda, "Structural and functional properties of ras proteins," FASEB Journal 3:2151-2163, 1989.
EK	Shih and Weeks, "Oncogenes and Cancer: The p21 ras Genes," Cancer Investigation 2(2):109-123, 1984.
EL	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," Science 244:707-712, 1989.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criterion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.525C3APPLICATION NO.
10/671,328**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever et al.

FILING DATE

September 24, 2003

GROUP ART UNIT

1764

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	FB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	FC	Smith, M.E.F. et al., "Variation in HLA Expression on Tumors: An Escape from Immune Response," in <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. 54, Cold Spring Harbor Laboratory Press, 1989, pgs. 581-586.
	FD	Stacey and Kung, "Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein," <i>Nature</i> 310:508-511, 1984.
	FE	Tanaka et al., "Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens," <i>Proc. Natl. Acad. Sci. USA</i> 82:3400-3404, 1985.
	FF	Thor et al., "Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases," <i>Nature</i> 311:302-303, 1984.
	FG	Weiner et al., "A point mutation in the neu oncogene mimics ligand induction of receptor aggregation," <i>Nature</i> 339:230-231, 1989.
	FH	Wisdom, G. B., "Enzyme immunoassay," <i>Clin Chem.</i> 22(8): 1243-1255, 1976.
	FI	Yandell et al., "Oncogenic Point Mutations in the Human Retinoblastoma Gene: Their Application to Genetic Counseling," <i>New England Journal of Medicine</i> 321:1689-1695, 1989.
	FJ	
	FK	
	FL	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criterion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).